Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.78 - $1.9 $18,065 - $44,005
-23,161 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.83 - $4.48 $7,122 - $17,436
-3,892 Reduced 14.39%
23,161 $42,000
Q4 2021

Feb 14, 2022

BUY
$2.35 - $5.58 $63,574 - $150,955
27,053 New
27,053 $129,000
Q3 2020

Nov 16, 2020

SELL
$3.7 - $5.47 $97,372 - $143,953
-26,317 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$4.59 - $8.96 $120,795 - $235,800
26,317 New
26,317 $121,000
Q3 2019

Nov 14, 2019

SELL
$2.47 - $3.51 $209,611 - $297,869
-84,863 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$3.06 - $51.61 $48,843 - $823,798
15,962 Added 23.17%
84,863 $268,000
Q1 2019

May 15, 2019

BUY
$31.16 - $48.62 $1.66 Million - $2.59 Million
53,353 Added 343.15%
68,901 $2.6 Million
Q4 2018

Feb 14, 2019

SELL
$23.33 - $36.37 $171,755 - $267,755
-7,362 Reduced 32.13%
15,548 $565,000
Q3 2018

Nov 14, 2018

SELL
$29.34 - $35.0 $80,685 - $96,250
-2,750 Reduced 10.72%
22,910 $786,000
Q2 2018

Aug 14, 2018

BUY
$27.33 - $41.46 $701,287 - $1.06 Million
25,660 New
25,660 $828,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.